Standard of care
OtherClinic-based HIV care
NCT Number: NCT03630549
This cluster-randomized trial tests a differentiated care model for HIV-positive individuals not on ART during a home-based HIV testing campaign in rural Lesotho, Southern Africa. In intervention clusters, patients are offered a differentiated ART delivery package with two features. Firstly, drug-refill and follow-up are provided by village health workers (VHW), reducing clinic visits to twice a year for laboratory assessment. Secondly, participants have the option of receiving individually tailored adherence reminders and viral load result notifications via SMS.
Looking for future studies?
Notify Me10 year and older
All sexes
Interventional
Phase 4
District of Butha-Buthe, Butha-Buthe, Lesotho
The VIBRA trial is a cluster randomized controlled, open-label, superiority trial in a resource-limited setting. The trial is linked to a another trial, the HOSENG (HOme-based SElf-testiNG) trial, that is described elsewhere (NCT03598686). Together, they consitute the GET ON (GETing tOwards Ninety) research project. The HOSENG study, with its home-based HIV testing campaign, provides the recruitment platform for the VIBRA study. The reasons for this interlinked design are: a) potential study participants for VIBRA trial (HIV-positive individuals not on ART) are to be recruited during a home-based HIV testing campaign and hence, it allows us to assess the entire HIV care cascade in one larger project, and b) both trials rely on interventions involving VHWs, who need to be randomized and specifically trained. Therefore, it is efficient and feasible to run both trials parallel and randomize at one time point only. The rational for a cluster randomized design is the reliance of the trial on the VHWs and, thus, the high risk of cross-contamination between the study arms if randomization would be done at individual level.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for clusters:
Exclusion criteria
for clusters:
Inclusion criteria
for individuals:
Exclusion criteria
individuals:
Clinic-based HIV care
Option to get ART refill and care by the village health worker
Other names: VIBRA
Time frame: 12 months (range: 10 - 15 months) after enrolment.
Viral suppression at 12 months, defined as the proportion of all participants with a VL <20 copies/mL
Time frame: 12 months (range: 10 - 15 months) after enrolment.
Viral suppression at 12 months, defined as the proportion of all participants with a VL <400 copies/mL
Time frame: 6 months (range 5 - 8 months) after enrolment
Viral suppression at 6 months, defined as the proportion of all participants with a VL <20 copies/mL
Time frame: 12 months (range 10 - 15 months) after enrolment.
The proportion of all participants with a VL <1000 copies/mL
Time frame: 6 months (range 5 - 8 months) after enrolment
The proportion of all participants with a VL <1000 copies/mL
Time frame: 12 months (range 5 - 15 months) after enrollment
The proportion of all participants with a VL <20 copies/mL at 6 (range 5 - 8 months) as well as at 12 months (range 10 - 15 months) after enrolment
Time frame: 30 days after enrollment
Linkage to care within 1 month, defined as the proportion of all participants attending the first clinic- or VHW-based ART visit at least once within 1 month after enrolment
Time frame: 90 days
Linkage to care within 3 months, defined as the proportion of all participants attending the first clinic- or VHW-based ART visit at least once within 3 months after enrolment
Time frame: 5-8 months after enrollment
The proportion of all participants active in care at a health facility or at the VHW 6 months (range 5 - 8 months) after enrollment
Time frame: 12 months (range 10 - 15 months) after enrolment
the proportion of all participants active in care at a health facility or at the VHW
Time frame: 12 months (range 10 - 15 months) after enrolment
The proportion of all participants who died
Time frame: 12 months (range 10 - 15 months) after enrollment
The proportion of all participants lost to follow-up
Time frame: 12 months (range 10 - 15 months) after enrolment
The proportion of all participants who transferred out to any other health facility (than the one initially registered) outside the study districts with a proof of transfer (documented proof of follow-up visit or laboratory test)
Time frame: 12 months (range 10 - 15 months) after enrolment
The proportion of all participants who transferred out to any other health facility (than the one initially registered) outside the study districts without a proof of transfer at 12 months (range 10 - 15 months) after enrolment
Niklaus Labhardt
Other
Village-based Refill of ART After Same-day ART Start vs Clinic-based ART Refill for HIV-positive Individuals Not on ART During Home-based HIV Testing (Part B of GET ON Research Project)
Acronym: VIBRA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05609513
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Kampala, Uganda
View Trial DetailsNCT06739915
Acquired Immunodeficiency Syndrome, Actinomycetales Infections
Soweto, Gauteng, South Africa
View Trial DetailsNCT04446611
Acquired Immunodeficiency Syndrome, Antenatal Care
East London, Eastern Cape, South Africa
View Trial DetailsNCT05121064
Acquired Immunodeficiency Syndrome, Alcohol-Related Disorders
Lusaka, Zambia
View Trial Details